Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Fanale

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Cancers|August 29, 2020
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond <i>BRCA1/2</i>Daniele Fanale, Lorena Incorvaia, Clarissa Filorizzo, et al.
Therapeutic Advances in Medical Oncology|June 18, 2019
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?Lorena Incorvaia, Giuseppe Badalamenti, Gaetana Rinaldi, et al.
Cancers|April 30, 2021
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?Daniele Fanale, Lorena Incorvaia, Giuseppe Badalamenti, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 5, 2016
Dietary restriction: could it be considered as speed bump on tumor progression road?Antonina Cangemi, Daniele Fanale, Gaetana Rinaldi, et al.
Cancers|May 9, 2020
Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in <i>BRCA1/2</i> GenesLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Oncotarget|August 31, 2015
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Giuseppe Bronte, Nicola Silvestris, Marta Castiglia, et al.
Advances in Therapy|August 22, 2019
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Expert Opinion on Therapeutic Targets|May 20, 2014
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?Daniele Fanale, Juan Lucio Iovanna, Ezequiel Luis Calvo, et al.
Oncoimmunology|November 12, 2020
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisionsLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Journal of Cellular Physiology|November 7, 2012
Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemnessRiccardo Di Fiore, Daniele Fanale, Rosa Drago-Ferrante, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Cancers|August 29, 2020
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond <i>BRCA1/2</i>Daniele Fanale, Lorena Incorvaia, Clarissa Filorizzo, et al.
Therapeutic Advances in Medical Oncology|June 18, 2019
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?Lorena Incorvaia, Giuseppe Badalamenti, Gaetana Rinaldi, et al.
Cancers|April 30, 2021
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?Daniele Fanale, Lorena Incorvaia, Giuseppe Badalamenti, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 5, 2016
Dietary restriction: could it be considered as speed bump on tumor progression road?Antonina Cangemi, Daniele Fanale, Gaetana Rinaldi, et al.
Cancers|May 9, 2020
Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in <i>BRCA1/2</i> GenesLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Oncotarget|August 31, 2015
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Giuseppe Bronte, Nicola Silvestris, Marta Castiglia, et al.
Advances in Therapy|August 22, 2019
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Expert Opinion on Therapeutic Targets|May 20, 2014
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?Daniele Fanale, Juan Lucio Iovanna, Ezequiel Luis Calvo, et al.
Oncoimmunology|November 12, 2020
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisionsLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Journal of Cellular Physiology|November 7, 2012
Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemnessRiccardo Di Fiore, Daniele Fanale, Rosa Drago-Ferrante, et al.
Pageof 7